Chemical Compound
Fosaprepitant dimeglumine
CAS Registry Number
265121-04-8
Primary Record
Fosaprepitant dimeglumine
- In stock
- 5,107 g
- Purity
- 99.3 %
- CAS
- 265121-04-8
Compound Identifiers & Properties
- CAS
- 265121-04-8
- PubChem CID
- 135564864
- SMILES
- C[C@H](C1=CC(=CC(=C1)C(F)(F)F)C(F)(F)F)O[C@@H]2[C@@H](N(CCO2)CC3=NN(C(=O)N3)P(=O)(O)O)C4=CC=C(C=C4)F.CNC[C@@H]([C@H]([C@@H]([C@@H](CO)O)O)O)O.CNC[C@@H]([C@H]([C@@H]([C@@H](CO)O)O)O)O
- Canonical SMILES
- CNC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO.CNC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO.C[C@@H](O[C@H]1OCCN(Cc2nn(P(=O)(O)O)c(=O)[nH]2)[C@H]1c1ccc(F)cc1)c1cc(C(F)(F)F)cc(C(F)(F)F)c1
Names & Synonyms
- Fosaprepitant dimeglumine
- Ivemend
- 265121-04-8
- Emend
- Fosaprepitant meglumine
- Fosaprepitant
- Aprepitant
- FOCINVEZ
- Fosaprepitant dimeglumine salt
- Proemend (TN)
- Emend for injection
- Fosaprepitantdimeglumine
- MK-0517
- RefChem:57106
- Fosaprepitant (dimeglumine)
- D35FM8T64X
- Fosaprepitant dimeglumine?
- UNII-D35FM8T64X
- Fosaprepitantdimegluminesalt
- Fosaprepitant dimeglumine [USAN]
- CHEBI:64311
- DTXSID50181095
- Fosaprepitant (as dimeglumine)
- Fosaprepitant meglumine (JAN)
- MFCD23102059
- VRQHBYGYXDWZDL-OOZCZQCLSA-N
- AMY380
- orb1307445
- CHEMBL1201782
- SCHEMBL29358080
- C37H56F7N6O16P
- DTXCID60103586
- Fosaprepitant dimeglumine (USAN)
- GLXC-05196
- HMS3885C05
- HY-14407AR
- EX-A1255
- ARD189163
- FOSAPREPITANT MEGLUMINE [JAN]
- HY-14407A
- NP2602
- s3038
- FOSAPREPITANT DIMEGLUMINE [MI]
- AKOS025401855
- AKOS026751492
- MK 0517 (Fosaprepitant dimeglumine)
- ACN-037209
- CCG-270607
- CS-1761
- FD46503
- Fosaprepitant (dimeglumine) (Standard)
- FOSAPREPITANT MEGLUMINE [MART.]
- FOSAPREPITANT MEGLUMINE [WHO-DD]
- C23H22F7N4O6P.2C7H17NO5
- FOSAPREPITANT DIMEGLUMINE [VANDF]
- AC-26397
- Fosaprepitant dimeglumine (as dimeglumine)
- SC-94648
- SY116089
- SW219389-1
- X3475
- A11069
- C74373
- D06597
- FOSAPREPITANT DIMEGLUMINE [ORANGE BOOK]
- A855468
- F979755
- L-758298
- Q27895904
- (2R,3R,4R,5S)-6-(Methylamino)hexane-1,2,3,4,5-pentaol ((3-(((2R,3S)-2-((R)-1-(3,5-bis(trifluoromethyl)phenyl)ethoxy)-3-(4-fluorophenyl)morpholino)methyl)-5-oxo-4,5-dihydro-1H-1,2,4-triazol-1-yl)phosphonate)(2:1)
- D-GLUCITOL, 1-DEOXY-1-(METHYLAMINO)-, (3-(((2R,3S)-2-((1R)-1-(3,5-BIS(TRIFLUOROMETHYL)PHENYL)ETHOXY)-3-(4-FLUOROPHENYL)-4-MORPHOLINYL)METHYL)-2,5-DIHYDRO-5-OXO-1H-1,2,4-TRIAZOL-1-YL)PHOSPHONATE (2:1) (SALT)
- (2R,3R,4R,5S)-6-(methylamino)hexane-1,2,3,4,5-pentaol hemi((3-(((2R,3S)-2-((R)-1-(3,5-bis(trifluoromethyl)phenyl)ethoxy)-3-(4-fluorophenyl)morpholino)methyl)-5-oxo-2,5-dihydro-1H-1,2,4-triazol-1-yl)phosphonate)
- (2R,3R,4R,5S)-6-(methylamino)hexane-1,2,3,4,5-pentaol hemi((3-(((2R,3S)-2-((R)-1-(3,5-bis(trifluoromethyl)phenyl)ethoxy)-3-(4-fluorophenyl)morpholino)methyl)-5-oxo-4,5-dihydro-1H-1,2,4-triazol-1-yl)phosphonate)
- (3-{[(2R,3S)-2-{(1R)-1-[3,5-Bis(trifluoromethyl)phenyl]ethoxy}-3-(4-fluorophenyl)morpholin-4-yl]methyl}-5-oxo-2,5-dihydro-1H-1,2,4-triazol-1-yl)phosphonic acid--1-deoxy-1-(methylamino)-D-glucitol (1/2)
- (3-{[(2R,3S)-2-{(1R)-1-[3,5-bis(trifluoromethyl)phenyl]ethoxy}-3-(4-fluorophenyl)morpholin-4-yl]methyl}-5-oxo-4,5-dihydro-1H-1,2,4-triazol-1-yl)phosphonic acid--1-deoxy-1-(methylamino)-D-glucitol (1/2)
- [3-[[(2R,3S)-2-[(1R)-1-[3,5-bis(trifluoromethyl)phenyl]ethoxy]-3-(4-fluorophenyl)morpholin-4-yl]methyl]-5-oxo-4H-1,2,4-triazol-1-yl]phosphonic acid;(2R,3R,4R,5S)-6-(methylamino)hexane-1,2,3,4,5-pentol
- 1-Deoxy-1-(methylamino)-D-glucitol [3-[[(2R,3S)-2-[(1R)-1-[3,5-bis(trifluoromethyl)phenyl]ethoxy]-3-(4-fluorophenyl)-4-morpholinyl]m ethyl]-2,5-dihydro-5-oxo-1H-1,2,4-triazol-1-yl]phosphonate
- 5-[[(2R,3S)-2-[(1R)-1-[3,5-bis(trifluoromethyl)phenyl]ethoxy]-3-(4-fluorophenyl)morpholin-4-yl]methyl]-2-phosphonato-1H-1,2,4-triazol-3-one;methyl-[(2S,3R,4R,5R)-2,3,4,5,6-pentahydroxyhexyl]ammonium
- BIS(1-DEOXY-1-(METHYLAMINO)-D-GLUCITOL) (3-(((2R,3S)-2-((1R)-1-(3,5-BIS(TRIFLUOROMETHYL)PHENYL)ETHOXY)-3-(4-FLUOROPHENYL)-4-MORPHOLINYL)METHYL)-2,5-DIHYDRO-5-OXO-1H-1,2,4-TRIAZOL-1-YL)PHOSPHONATE
- bis[1-deoxy-1-(methylazaniumyl)-D-glucitol] (3-{[(2R,3S)-2-{(1R,)-1-[3,5-bis(trifluoromethyl)phenyl]ethoxy}-3-(4-fluorophenyl)morpholin-4-yl]methyl}-5-oxo-4,5-dihydro-1H-1,2,4-triazol-1-yl)phosphonate
- D-Glucitol, 1-deoxy-1-(methylamino)-, (3-(((2R,3S)-2-((1R)-1-(3,5-bis(trifluoromethyl)phenyl)ethoxy)-3-(4-fluorophenyl)-4- morpholinyl)methyl)-2,5-dihydro-5-oxo-1H-1,2,4-triazol-1-yl)phosphonate (2:1) (salt)
- D-Glucitol, 1-deoxy-1-(methylamino)-, [3-[[(2R,3S)-2-[(1R)-1-[3,5-bis(trifluoromethyl)phenyl]ethoxy]-3-(4-fluorophenyl)-4-morpholinyl]methyl]-2,5-dihydro-5-oxo-1H-1,2,4-triazol-1-yl]phosphonate (2:1); D-Glucitol, 1-deoxy-1-(methylamino)-, [3-[[(2R,3S)-2-[(1R)-1-[3,5-bis(trifluoromethyl)phenyl]ethoxy]-3-(4-fluorophenyl)-4-morpholinyl]methyl]-2,5-dihydro-5-oxo-1H-1,2,4-triazol-1-yl]phosphonate (2:1) (salt) (9CI); Phosphonic acid, [3-[[(2R,3S)-2-[(1R)-1-[3,5-bis(trifluoromethyl)phenyl]ethoxy]-3-(4-fluorophenyl)-4-morpholinyl]methyl]-2,5-dihydro-5-oxo-1H-1,2,4-triazol-1-yl]-, compd. with 1-deoxy-1-(methylamino)-D-glucitol (1:2) (9CI); Fosaprepitant di(N-methylglucamine); Fosaprepitant dimeglumine; MK 0517
- Phosphonic acid, (3-(((2R,3S)-2-((1R)-1-(3,5-bis(trifluoromethyl)phenyl)ethoxy)-3-(4-fluorophenyl)-4-morpholinyl)methyl)-2,5-dihydro-5-oxo-1H-1,2,4-triazol-1-yl)-, compd. with 1-deoxy-1-(methylamino)-D-glucitol (1:2)